Hyperphosphorylation of tau is a key pathological feature in Alzheimer’s disease (AD), and studies have established the critical role of MARK4 in this event (Annadurai et al., 2017). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.